The Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) approved the start of a clinical study of a booster dose with the anticovid-19 vaccine candidate Mambisa, in previously vaccinated subjects, to evaluate the effect and the safety of this immunogen, which is applied directly through the nasal route.
Mambisa, applied by nasal spray, drop dispenser or by means of a Cuban syringe device, is a unique formulation based on the receptor binding domain (RBD) of the spike protein of the SARS virus -CoV-2.
Its purpose is to introduce antibodies that interfere with the entry of the pathogen into cells; mechanism that is essential to generate protection.
comments on